Skip to main content
SpringerLink
Log in

Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

The objective of this study is to detect the expression of midkine (MK) in papillary thyroid cancer (PTC) and to evaluate whether MK expression is associated with clinicopathological features and BRAF mutation in PTC. The expression of MK in samples from 200 cases of PTC, 60 cases of adenomatoid nodule of thyroid, and 40 samples of tumor-adjacent normal thyroid tissue were assessed with immunohistochemistry. The BRAF mutation was detected by direct sequencing. The relationships between MK expression and the clinicopathological features of PTC and BRAF mutation were analyzed. The results demonstrated that MK was not expressed in tumor-adjacent normal tissue. The positive expression rates and MK scores were both higher in PTC than in adenomatoid nodule (positive expression rates: 88 vs. 8.3 %, P < 0.001; MK scores: 2.02 ± 0.93 vs. 0.08 ± 0.28, P < 0.001). The expression level of MK in PTC with extrathyroidal invasion, lymph node metastasis, or stage III/IV was significantly higher than that in PTC without such biological features (all P < 0.01). The overall prevalence of BRAF mutation was 66.5 % in PTC. The expression level of MK in PTC with BRAF mutation was significantly higher than that in PTC with wild-type BRAF (P < 0.001). We can conclude that MK is specifically expressed in PTC tissues and is associated with clinicopathological features and BRAF mutation. MK may be a helpful diagnostic and prognostic marker for PTC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. L. Davies, H.G. Welch, Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295(18), 2164–2167 (2006)

    Article  CAS  PubMed  Google Scholar 

  2. E.L. Mazzaferri, S.M. Jhiang, Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 97(5), 418–428 (1994)

    Article  CAS  PubMed  Google Scholar 

  3. M. Xing, BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr. Rev. 28(7), 742–762 (2007)

    Article  CAS  PubMed  Google Scholar 

  4. J.A. Knauf, X. Ma, E.P. Smith, L. Zhang, N. Mitsutake, X.H. Liao, S. Refetoff, Y.E. Nikiforov, J.A. Fagin, Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 65(10), 4238–4245 (2005)

    Article  CAS  PubMed  Google Scholar 

  5. N. Kurtulmus, M. Duren, U. Ince, M.C. Yakicier, O. Peker, O. Aydin, A. Ender, S. Giray, H. Azizlerli, BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine 42(2), 404–410 (2012)

    Article  CAS  PubMed  Google Scholar 

  6. K. Kadomatsu, M. Tomomura, T. Muramatsu, cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis. Biochem. Biophys. Res. Commun. 151(3), 1312–1318 (1988)

    Article  CAS  PubMed  Google Scholar 

  7. J. Tsutsui, K. Kadomatsu, S. Matsubara, A. Nakagawara, M. Hamanoue, S. Takao, H. Shimazu, Y. Ohi, T. Muramatsu, A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms’ tumor and other human carcinomas. Cancer Res. 53(6), 1281–1285 (1993)

    CAS  PubMed  Google Scholar 

  8. K. Ota, H. Fujimori, M. Ueda, H. Jono, S. Shinriki, T. Ota, T. Sueyoshi, M. Taura, A. Taguma, H. Kai, M. Shinohara, Y. Ando, Midkine expression is correlated with an adverse prognosis and is down-regulated by p53 in oral squamous cell carcinoma. Int. J. Oncol. 37(4), 797–804 (2010)

    CAS  PubMed  Google Scholar 

  9. Li.L. Qin, H.L. Huang, J.L. Ping, W. Xu, J. Li, L.C. Dai, Expression of midkine and endoglin in breast carcinomas with different immunohistochemical profiles. APMIS 119(2), 103–110 (2011)

    Article  Google Scholar 

  10. G.E. Rice, T.A. Edgell, D.J. Autelitano, Evaluation of midkine and anterior gradient 2 in a multimarker panel for the detection of ovarian cancer. J. Exp. Clin. Cancer. Res. 29, 62 (2010)

    Article  PubMed Central  PubMed  Google Scholar 

  11. A. Nordin, W. Wang, K. Welén, J.E. Damber, Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer. Prostate 73(6), 657–667 (2013)

    Article  CAS  PubMed  Google Scholar 

  12. S. Kishida, P. Mu, S. Miyakawa, M. Fujiwara, T. Abe, K. Sakamoto, A. Onishi, Y. Nakamura, K. Kadomatsu, Midkine promotes neuroblastoma through Notch2 signaling. Cancer Res. 73(4), 1318–1327 (2013)

    Article  CAS  PubMed  Google Scholar 

  13. D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11), 1167–1214 (2009)

    Article  PubMed  Google Scholar 

  14. F. Pacini, Changing natural history of differentiated thyroid cancer. Endocrine 42(2), 229–230 (2012)

    Article  CAS  PubMed  Google Scholar 

  15. T. Kunavisarut, Diagnostic biomarkers of differentiated thyroid cancer. Endocrine (2013). doi:10.1007/s12020-013-9974-2

    PubMed  Google Scholar 

  16. A. Guerra, V. Marotta, M. Deandrea, M. Motta, P.P. Limone, A. Caleo, P. Zeppa, S. Esposito, F. Fulciniti, M. Vitale, BRAF(V600E) associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma. Endocrine 44(1), 165–171 (2012)

    Article  PubMed  Google Scholar 

  17. M. Kato, H. Maeta, S. Kato, T. Shinozawa, T. Terada, Immunohistochemical and in situ hybridization analyses of midkine expression in thyroid papillary carcinoma. Mod. Pathol. 13(10), 1060–1065 (2000)

    Article  CAS  PubMed  Google Scholar 

  18. M. Xing, BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 12(2), 245–262 (2005)

    Article  CAS  PubMed  Google Scholar 

  19. E. Puxeddu, C. Durante, N. Avenia, S. Filetti, D. Russo, Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol. Metab. 19(4), 138–145 (2008)

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was financially supported by the National Science Foundation of China (Grant # 3080112), the Key Laboratory Program Foundation of Education Department of Liaoning Province (Grant # LS2010163), and the Fund for Scientific Research of The First Hospital of China Medical University (Grant # FSFH1202).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China

    Hua Shao & Qiang Wang

  2. Department of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China

    Xiaohui Yu & Haixia Guan

  3. Department of Pathology, Feng Tian Hospital of Shenyang Medical College, Shenyang, 110024, China

    Cuifang Wang

Authors
  1. Hua Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaohui Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cuifang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qiang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Haixia Guan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Qiang Wang or Haixia Guan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shao, H., Yu, X., Wang, C. et al. Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer. Endocrine 46, 285–291 (2014). https://doi.org/10.1007/s12020-013-0068-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-013-0068-y

Keywords

Search

Navigation